Quantum-Si Incorporated

Quantum-Si Incorporated

NNASDAQ:QSI
1.06
USD
-0.09
(-7.83%)
-0.39EPS
235.12MMarket Cap
Mar 08Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
0.02
0.01
0.01
Basic EPS, GAAP
-0.26
-0.27
-1.19
-0.95
-0.69
-0.71
-0.51
-0.39
Free Cash Flow per Basic Share
-0.23
-0.24
-0.91
-0.73
-0.71
-0.65
-0.49
-0.38
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-1.17
3.46
2.56
1.92
1.29
1.02
0.73
Tangible Book Value per Share
- -
-1.17
3.39
2.56
1.91
1.29
1.02
0.73
Basic Weighted Avg Shares
136
136
80
139
139
143
198
216
Sales/Revenue/Turnover
- -
- -
- -
- -
1
3
2
1
Operating Margin (%)
- -
- -
- -
- -
-10,274.58
-3,550.56
-3,996.72
-7,474.47
Depreciation Expense
1
1
1
3
4
5
4
5
Net Income, GAAP
-36
-37
-95
-132
-96
-101
-101
-85
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-8,868.76
-3,303.04
-4,160.06
-6,729.8
Working Capital
- -
35
466
342
255
200
153
101
LT Debt
- -
2
7
16
14
9
2
1
Total Equity
- -
36
477
359
272
215
220
160
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-31.69
-30.45
-41.48
-46.52
-43.06

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
217
219
220
Market Capitalization
168
194
235

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
135
119
112
Cash, Cash Equivalents & STI
127
112
104
Accounts Receivable, Net
- -
- -
- -
Inventories
2
2
2
Total Current Liabilities
11
12
12
Payables & Accruals
8
9
9
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
230.86%
2.23%
Free Cash Flow
- -
31.11%
5.26%
Net Income, GAAP
- -
35.38%
0.33%
Sales/Revenue/Turnover
- -
- -
-20.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
1
1
3
2025
1
1
1
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.16
-0.18
-0.23
-0.71
2025
-0.11
-0.16
-0.17
-0.08
-0.51
2026
-0.1
-0.11
-0.1
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jeffrey Alan Hawkins
Full Time Employees
145
Sector
Technology services
Industry
Packaged software
Address
29 Business Park Drive Branford CT United States 06405
IPO Date
Sep 4, 2020
Business
Quantum-Si Incorporated develops and commercializes advanced protein sequencing technologies through its proprietary single-molecule detection platform. Its core products include the Platinum and Platinum Pro Next-Generation Protein Sequencers™, which enable single-molecule, single-amino-acid resolution sequencing for research use. The company also offers consumables such as library preparation kits, barcoding kits, sequencing kits, and the Platinum Analysis Software, a cloud-based solution that automates data workflows and provides comprehensive visualization for protein analysis. These products support applications in antibody characterization, biomarker identification, protein variant detection, protein barcoding, and post-translational modification analysis. Quantum-Si serves research laboratories and biopharmaceutical companies globally from its headquarters in Branford, Connecticut, and operates within the life sciences and proteomics industry. Recent major developments include the global launch and shipping of the Platinum Pro sequencer in early 2025, featuring enhanced user interfaces, cloud and on-instrument data analysis, and a Pro Mode for custom applications. In 2024, the company introduced new consumables such as the v2 Library Preparation Kit and a new Barcoding Kit, with the v4 Sequencing Kit scheduled for launch in the third quarter of 2025. Quantum-Si is developing a next-generation proteomics platform named Proteus, targeting a mid-2026 launch. Proteus promises ultrasensitive proteoform detection, rapid sequencing chemistry reducing run time to 90 minutes or less, and automated liquid handling to boost sample throughput. The company has expanded strategic collaborations, including a partnership with Planet Innovation for development and manufacturing of the Proteus platform and a collaboration with SkyWater Technology to advance chip production for these platforms. In September 2025, Quantum-Si entered a sales agreement to offer up to $100 million of Class A common stock to strengthen its financial flexibility. Founded in 2013, Quantum-Si integrates biology, chemistry, and artificial intelligence to advance proteomics beyond traditional methods, aiming to revolutionize drug discovery and diagnostics. It operates primarily in the United States, serving the global research and biopharmaceutical communities. Its strategic product evolution and partnerships position Quantum-Si as a pioneer in delivering accessible, high-resolution protein sequencing solutions. This description consolidates Quantum-Si’s core products, recent technological advancements, strategic partnerships, and financial activities through 2024 and 2025.

Company News

  • Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Quantum-Si Q3 Earnings Call Highlights

  • Quantum-Si incorporated (QSI) Q3 2026 Earnings Call Transcript

  • Quantum-Si Incorporated (QSI) Reports Q3 Loss, Misses Revenue Estimates

  • Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Head-To-Head Comparison: Quantum-Si (NASDAQ:QSI) vs. Quanterix (NASDAQ:QTRX)

  • Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026

  • Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Leading Indicators For The October Breakout Cycle

  • Beyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Race

  • Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program

  • Head to Head Survey: Quantum-Si (NASDAQ:QSI) versus Twist Bioscience (NASDAQ:TWST)

  • Neuralink Stock: How to Invest Before the IPO

  • 3 Biotech Stocks Put Traders Are Targeting Today

  • Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

  • Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

  • Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

  • Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript

  • Quantum-Si Q2 Earnings Call Highlights